Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 20 | 2023 | 2207 | 1.240 |
Why?
|
| Medication Adherence | 3 | 2019 | 165 | 0.640 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2020 | 375 | 0.470 |
Why?
|
| Ambulatory Care Facilities | 2 | 2017 | 61 | 0.460 |
Why?
|
| Case Management | 1 | 2011 | 21 | 0.410 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2017 | 55 | 0.390 |
Why?
|
| Anti-Retroviral Agents | 2 | 2019 | 139 | 0.390 |
Why?
|
| Anti-HIV Agents | 4 | 2017 | 394 | 0.370 |
Why?
|
| Homosexuality, Male | 4 | 2019 | 438 | 0.370 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2005 | 219 | 0.350 |
Why?
|
| Contact Tracing | 1 | 2007 | 17 | 0.320 |
Why?
|
| Sexual Partners | 7 | 2020 | 308 | 0.320 |
Why?
|
| Hepatitis C | 2 | 2023 | 120 | 0.320 |
Why?
|
| Community-Institutional Relations | 2 | 2017 | 171 | 0.310 |
Why?
|
| Drug Resistance, Viral | 2 | 2005 | 60 | 0.310 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2020 | 165 | 0.270 |
Why?
|
| HIV-1 | 4 | 2017 | 678 | 0.260 |
Why?
|
| Los Angeles | 7 | 2022 | 368 | 0.260 |
Why?
|
| Didanosine | 1 | 2003 | 2 | 0.250 |
Why?
|
| Nevirapine | 1 | 2003 | 7 | 0.240 |
Why?
|
| Oxazines | 1 | 2003 | 23 | 0.240 |
Why?
|
| HIV | 1 | 2004 | 97 | 0.230 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 39 | 0.230 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 90 | 0.200 |
Why?
|
| Humans | 22 | 2023 | 34853 | 0.190 |
Why?
|
| Social Support | 3 | 2013 | 356 | 0.190 |
Why?
|
| Male | 16 | 2020 | 18870 | 0.180 |
Why?
|
| Communication Barriers | 1 | 2020 | 53 | 0.180 |
Why?
|
| Mass Screening | 2 | 2014 | 427 | 0.180 |
Why?
|
| Hepacivirus | 2 | 2023 | 59 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 187 | 0.170 |
Why?
|
| Adult | 13 | 2023 | 11034 | 0.170 |
Why?
|
| Patient Compliance | 3 | 2017 | 202 | 0.160 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 8 | 0.160 |
Why?
|
| Condoms | 1 | 2019 | 132 | 0.160 |
Why?
|
| Sexual Behavior | 3 | 2017 | 587 | 0.150 |
Why?
|
| United States | 7 | 2013 | 3894 | 0.150 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 165 | 0.150 |
Why?
|
| Adolescent | 6 | 2017 | 5035 | 0.140 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2017 | 123 | 0.140 |
Why?
|
| Female | 13 | 2020 | 19873 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2014 | 33 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2014 | 790 | 0.120 |
Why?
|
| Young Adult | 5 | 2017 | 4012 | 0.120 |
Why?
|
| Risk-Taking | 5 | 2017 | 435 | 0.110 |
Why?
|
| Viral Load | 3 | 2022 | 300 | 0.110 |
Why?
|
| Health Personnel | 1 | 2014 | 200 | 0.100 |
Why?
|
| Truth Disclosure | 1 | 2011 | 24 | 0.100 |
Why?
|
| Stereotyping | 1 | 2011 | 40 | 0.100 |
Why?
|
| Stress, Psychological | 3 | 2013 | 541 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 186 | 0.100 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 11 | 0.100 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 13 | 0.100 |
Why?
|
| Risk Factors | 4 | 2013 | 3414 | 0.100 |
Why?
|
| Antigen Presentation | 1 | 2010 | 54 | 0.100 |
Why?
|
| Sexuality | 1 | 2010 | 50 | 0.090 |
Why?
|
| Middle Aged | 7 | 2017 | 9642 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2007 | 110 | 0.080 |
Why?
|
| Depression | 1 | 2013 | 664 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 118 | 0.070 |
Why?
|
| Chicago | 1 | 2005 | 24 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2005 | 38 | 0.070 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 119 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2007 | 727 | 0.060 |
Why?
|
| Professional-Patient Relations | 1 | 2004 | 44 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2010 | 1422 | 0.060 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 8 | 0.060 |
Why?
|
| Cyclopropanes | 1 | 2003 | 39 | 0.060 |
Why?
|
| Alkynes | 1 | 2003 | 49 | 0.060 |
Why?
|
| Benzoxazines | 1 | 2003 | 46 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 145 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 63 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 1353 | 0.060 |
Why?
|
| Logistic Models | 3 | 2013 | 894 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 185 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2023 | 148 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2003 | 287 | 0.050 |
Why?
|
| California | 2 | 2013 | 436 | 0.050 |
Why?
|
| AIDS Serodiagnosis | 1 | 2020 | 25 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 2561 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1003 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2003 | 1349 | 0.040 |
Why?
|
| Adenine | 1 | 2019 | 43 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 577 | 0.040 |
Why?
|
| Ritonavir | 1 | 2017 | 14 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2003 | 1961 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2017 | 60 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2019 | 161 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2017 | 52 | 0.040 |
Why?
|
| Patient Selection | 1 | 2017 | 154 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 159 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 841 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 628 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2014 | 80 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 225 | 0.030 |
Why?
|
| Morbidity | 1 | 2013 | 94 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2013 | 136 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 243 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 393 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 310 | 0.030 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 4 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 7 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 5 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 6 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 152 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 139 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 135 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 284 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 150 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 350 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 271 | 0.020 |
Why?
|
| Bisexuality | 1 | 2011 | 202 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 580 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 751 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 638 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 570 | 0.020 |
Why?
|
| Aged | 1 | 2014 | 6448 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 195 | 0.010 |
Why?
|